[144] AGIOS PHARMACEUTICALS, INC. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for AGIO (Agios Pharmaceuticals, Inc.) reporting a proposed sale of 3,651 shares of common stock via Morgan Stanley Smith Barney. The filing states the aggregate market value of the shares is $134,247.00 and lists 58,101,518 shares outstanding. The securities were acquired through the vesting of restricted stock units on 09/26/2025 and the same date is shown as the approximate sale date and payment date. The filer reports no securities sold in the past three months.

Positive

• Full disclosure of sale details: acquisition date, nature (vesting of RSUs), broker, share count, and aggregate value are provided
• No sales in past three months, simplifying aggregation and indicating this is not part of a series of recent disposals
• Transaction size is immaterial relative to outstanding shares (3,651 shares vs. 58,101,518 outstanding)

Negative

• None.

Insights

Securities Analyst

TL;DR: Small, routine insider sale from vested RSUs reported through Form 144; no prior sales in the past three months.

The filing documents a proposed sale of 3,651 shares acquired on 09/26/2025 through the vesting of restricted stock units and scheduled for sale on the same date through Morgan Stanley Smith Barney. The aggregate market value is stated as $134,247 against 58,101,518 shares outstanding, indicating the transaction represents a minute fraction of the outstanding float. The filer also certifies no material nonpublic information is known. This appears to be a standard Rule 144 notice for an insider monetizing vested equity rather than a material disposition that would affect company valuation.

Corporate Governance Expert

TL;DR: Proper Form 144 disclosure for vested RSUs; demonstrates compliance with resale reporting requirements.

The document shows the person is relying on Rule 144 procedures by filing a Form 144 and disclosing acquisition and intended sale details. The inclusion of acquisition method (vesting of RSUs), broker details, and the representation about material nonpublic information aligns with expected insider disclosure practices. There are no reported sales in the prior three months, which simplifies aggregation rules for this filing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3651	134247.00	58101518	09/26/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/26/2025	Vesting of Restricted Stock Units	Issuer			3651	09/26/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does AGIO's Form 144 report?

The filing reports a proposed sale of 3,651 common shares acquired via vesting of RSUs on 09/26/2025, with an aggregate market value of $134,247.00.

Who is the broker handling the proposed sale in AGIO's Form 144?

The broker listed is Morgan Stanley Smith Barney LLC Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.

When is the approximate sale date reported in the Form 144 for AGIO?

The approximate date of sale is reported as 09/26/2025.

How large is the proposed sale compared with AGIO's outstanding shares?

The filing shows 3,651 shares proposed for sale versus 58,101,518 shares outstanding, a very small percentage of total outstanding shares.

Were any AGIO shares sold by the filer in the past three months?

The filing states Nothing to Report for securities sold during the past three months.